MedTrace Logo

HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients

NCT04516850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-04-25

No results posted yet for this study

Summary

The study includes 2 sub-projects.

Sub-project 1: The aim is to evaluate the expression of receptors and activating proteases mediating SARS-CoV-2 entry and spreading in the local population of Ticino.

Sub-project 2: The aim is to investigate the association between the HSD3B1 gene variations and outcome of COVID-19 in the local population of Ticino.

Conditions

  • Covid19

Interventions

GENETIC

Expression of receptors and activating proteases

Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19

GENETIC

Polymorphism of the HSD3B1

Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)

Sponsors & Collaborators

  • Institute of Oncology Research (IOR)

    collaborator UNKNOWN

  • Istituto Cantonale di Patologia

    collaborator OTHER

  • Ricardo Pereira Mestre

    lead OTHER

Principal Investigators

  • Ricardo Pereira Mestre, MD · Oncology Institute of Southern Switzerland (IOSI)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2023-02-21
Completion
2023-02-21

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516850 on ClinicalTrials.gov